Skip to main content
PIPELINE > TRIAL OVERVIEW

Trial Information
Molecule Overview
FRα Antibody-Drug Conjugate
LY4170156
Phase
3
Recruiting
Recruiting Info
FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Related Resources:
FRAmework-01 Trial
Key Inclusion Criteria
  • Part A and B:
    • Have histologically confirmed high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
    • Have confirmed availability of tumor tissue block or slides
    • Have radiographic progression on or after most recent line of systemic anticancer therapy
    • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
    • Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Part A:
    • Have platinum-resistant disease, defined as radiographic progression ≤6 months of the last administration of platinum therapy
    • Have previously received ≥1 but ≤3 prior lines of systemic cytotoxic therapy. Up to 4 lines of prior therapy is allowed if one of those lines is mirvetuximab soravtansine
    • Have received prior bevacizumab treatment, unless documented contraindication or intolerance
    • Have received treatment with a poly(ADP-ribose) polymerase inhibitor (PARPi) if known to have a somatic or germline breast cancer gene (BRCA) mutation, if clinically indicated, unless documented contraindication or intolerance
  • Part B:
    • Have relapsed after first-line platinum-based chemotherapy and have platinum-sensitive disease defined as radiographic progression >6 months of their last administration of platinum therapy
    • Have previously received ≥1 but ≤2 prior lines of systemic cytotoxic chemotherapy
    • Have previously received a PARPi, per local product label, with progression on or within 6 months of completion of PARPi treatment
Key Exclusion Criteria
  • Part A and B:
    • Have received prior antibody-drug conjugate (ADC) with a topoisomerase inhibitor payload
  • Part A:
    • Have primary platinum-refractory disease, defined as disease that progressed ≤3 months since the last dose of first-line platinum-containing chemotherapy
  • Part B:
    • Have clinically significant proteinuria
a
Stratified by high FRα expression (≥75% of cells with ≥2+ staining intensity); prior MIRV use; and Investigator’s choice therapy: paclitaxel versus other chemotherapy versus MIRV.
b
3 mg/kg, administered intravenously every 3 weeks (Q3W).
c
Paclitaxel, PLD, gemcitabine or topotecan.
d
Mirvetuximab if eligible, where available.
e
Stratified by platinum-free interval ≥12 months vs <12 months; 1st vs 2nd disease recurrence; carboplatin + PLD vs others; FRα ≥75% vs FRα <75%.
f
Carboplatin+paclitaxel or carboplatin+gemcitabine or carboplatin+PLD.
For information on trial enrollment, locations, and more, call 1-800-545-5979.
REQUEST A MEDICAL SCIENCE LIAISON

or visit www.clinicaltrials.gov for more information on this trial